In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) …
See Original Article

The FCA has established a new advisory committee to the FCA’s Board to work on Environmental, Social and Governance (ESG) issues. Earlier this year the FCA Board agreed to establish a new ESG Advisory Committee to help execute its ESG-related …
See Original Article

Collaboration to explore potential of creating next-generation antibody-drug conjugates with Biosion’s SynTracer® internalization platform and ImmunoGen’s proprietary linker-payload technology. NEWARK, Del., Dec. 13, 2022 /PRNewswire/ — Biosion USA, …
See Original Article